CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study

Go back to CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
Johnson & Johnson (NYSE: JNJ) Delayed: 256.99 -2.37 (0.91%)
Previous Close $259.36    52 Week High $126.07 
Open $257.50    52 Week Low $94.28 
Day High $257.75    P/E 53.43 
Day Low $254.56    EPS $4.81 
Volume 3,004,791